Overcoming membrane protein complexes using display technologies
28 Apr 2026
Target Selection & Mechanisms of Action
- Why is tumor microenvironment (TME) reprogramming emerging as a critical frontier beyond checkpoint blockade?
- Why have many TME-directed antibody programs underperformed despite strong biological rationale?
- What biomarkers most reliably validate mechanism of action in immune-cold or immunotherapy-resistant tumors?
- How should multi-modal approaches (bispecifics, ADCs, and immune modulators) be rationally designed to achieve meaningful TME reprogramming?
- Can next-generation ADCs and spatially informed targeting strategies intentionally modulate the TME—not just kill tumor cells?
Industry Expert
